Defendants In Securities Class Action Against Drug Maker Seek Dismissal
NEW YORK — Dismissal of a second amended shareholder class action lawsuit against a drug maker and certain of its current and former executive officers is warranted because the lead plaintiff...To view the full article, register now.
Already a subscriber? Click here to view full article